Kornimate/medical-research-clean huggingface dataset:
contribution of the imaging to the expression of intégrines αvβ3 for the characterization of residual masses of non-seminoma tumors at the end of chemotherapy

Conditions: Non-seminomatous Germ Cell Tumors; Metastasis

Summary: the purpose of this study is to evaluate the contribution of the imaging to the expression of intégrines αvβ3 for the characterization of the residual masses of non-seminoma tumors at the end of chemotherapy. the investigators hope that the results of this first stage of the clinical trial come to consolidate the preclinical results obtained by the investigators team to characterizing the interest and the strong contribution of the use of a tracer resting on the expression of αvβ3 integrine for the diagnosis of simple necrosed mass at the end of the treatment of a non-seminoma tumor, so allowing to defer a surgery to about 40 % of the patients.


Eligibility criteria:
inclusion criteria: * man or woman aged 18 years or more * patients with one or several ganglionic or visceral residual masses (\> to 1 cm) after chemotherapy for metastatic non-seminoma testicular tumor, and for which or which a surgery is planned; * affiliate to a social security system; * signed written informed consent exclusion criteria: * patient deprived of liberty as a result of a justice or administrative decision * any medical or psychological condition which could compromise the capacity of the patient to participate in the study; * previous or concomitant other cancer in 5 years except basal cell carcinomas

Keywords: nuclear medicine positron emission tomography avb3 integrin expression
bingo drug-coated balloon in real world

Conditions: Coronary Stenosis; Drug-coated Balloon; De Novo Stenosis; Coronary Artery Disease in Transplanted Heart Accelerated

Summary: the purpose is to observe and evaluate the safety and efficacy of bingo drug-coated balloon in the real world.


Eligibility criteria:
inclusion criteria: 1. age 18 or older, regardless of gender; 2. patients suitable for pci with paclitaxel drug-coated balloon; 3. patients able to understand the purpose of this study, provide an informed consent and cooperate with clinical follow-up. exclusion criteria: general exclusion criteria 1. contraindications to pci; 2. in-stent restenosis; 3. life expectation less than 1 year; 4. patients not suitable for enrollment considered by investigator. angiographic exclusion criteria: 1. target lesion with the following conditions after pre-dilatation: 1. residual stenosis larger than 30% ; 2. timi flow grade less than 3; 3. type c-f dissection (nhlbi grade).

Keywords: coronary stenosis percutaneous coronary intervention drug-coated balloon drug eluting balloon paclitaxel de novo bifurcation coronary artery disease
correction of zinc deficiency in children with chronic kidney disease and kidney transplant

Conditions: Renal Insufficiency, Chronic; Zinc Deficiency; Trace Element Excess; Trace Element Deficiency

Summary: children with chronic kidney disease, even after transplantation, may be at risk for bone problems due to an imbalance of calcium and phosphorus in the blood, especially as their kidneys progressively fail to function. while some drug and diet treatments are available to prevent such bone disease, many children refuse to take them due to bad taste and tummy cramps. if calcium and phosphorus status remain abnormal for a long time, hard crystals can form in the blood vessels, eventually clogging them and resulting in heart problems. investigators are studying possible new methods to help the kidneys maintain a normal balance of nutrients in the blood which is important for growing healthy bones and the prevention of side effects in blood vessels that can lead to heart disease. one method is to improve the team work of a hormone fgf-23 and a protein called klotho that together stimulate the kidneys to increase phosphate removal. investigators propose that this problem may be due to low blood zinc levels which often occur in children with kidney disease. thus, in this study, investigators propose to first measure zinc in blood from children with chronic kidney disease (ckd) or who have had kidney transplants to assess zinc and phosphate status, the hormone fgf-23 and its assistant klotho. if zinc status is low, the children will receive zinc supplementation for 3 months. after treatment with zinc, the same blood measurements will be repeated to determine if the zinc supplements have helped the hormones to remove phosphate from the body. if this pilot project is successful, investigators will then consider a larger scale project involving adult patients as well as pediatric patients from other pediatric centers. this project will also guide investigators as to whether they need to introduce zinc measurements as part of routine testing of ckd and transplant patients. in addition to measuring zinc levels in study participants, trace elements (te) will also be measured. these include heavy metals such as cadmium, chromium, nickel, vanadium, copper, lead, manganese and selenium. very little is known about levels and metabolism of te in ckd especially before dialysis. in adults, cadmium, chromium, nickel, and vanadium probably accumulate in hemodialysis patients, while copper and lead may accumulate. manganese, selenium are probably deficient. the study will allow investigators to obtain the information about te in this group of pediatric patients.


Eligibility criteria:
inclusion criteria: * children between 4 and 18 years of age; diagnosis of ckd; renal transplant recipient with declining renal function (egfr\<90 ml/min/1.73 m2). exclusion criteria: * children with ckd or kidney transplant younger than 4 years. kidney transplant recipients with egfr\>90 ml/min/1.73 m2.
docetaxel in treating patients with persistent or recurrent cervical cancer

Conditions: Cervical Squamous Cell Carcinoma, Not Otherwise Specified; Recurrent Cervical Carcinoma

Summary: phase ii trial to study the effectiveness of docetaxel in treating patients who have persistent or recurrent cervical cancer. drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

primary objectives: i. determine the antitumor activity of docetaxel in patients with persistent or recurrent squamous cell carcinoma of the cervix. ii. determine the toxicity of this drug in these patients. outline: this is a multicenter study. patients receive docetaxel iv over 1 hour on day 1. courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

Eligibility criteria:
inclusion criteria: * histologically confirmed persistent or recurrent squamous cell carcinoma of the cervix * progressive disease * at least 1 unidimensionally measurable target lesion * at least 20 mm by conventional techniques * at least 10 mm by spiral ct scan * tumors within a previously irradiated field are not considered target lesions * one prior systemic chemotherapeutic regimen for advanced, metastatic, or recurrent squamous cell carcinoma of the cervix required * chemotherapy administered as a radiosensitizer in conjunction with primary radiotherapy is not considered a systemic chemotherapy regimen * ineligible for a higher priority gog protocol (e.g., any active phase iii gog protocol or gog-0076) * performance status - gog 0-2 * absolute neutrophil count at least 1,500/mm3 * platelet count at least 100,000/mm3 * bilirubin no greater than 1.5 times upper limit of normal (uln) * sgot no greater than 2.5 times uln * alkaline phosphatase no greater than 2.5 times uln * creatinine no greater than 1.5 times uln * no congestive heart failure * no unstable angina, myocardial infarction, or new cardiac arrhythmia within the past 6 months * negative pregnancy test * fertile patients must use effective contraception * no active infection requiring antibiotics * no greater than grade 1 sensory and motor neuropathy * no other invasive malignancy within the past 5 years except nonmelanoma skin cancer * at least 3 weeks since prior biologic or immunologic therapy directed at malignant tumor * one prior noncytotoxic regimen (e.g., monoclonal antibodies, cytokines, or small-molecule signal transduction inhibitors) for recurrent or persistent disease allowed * recovered from prior chemotherapy * no prior docetaxel * no more than 1 prior cytotoxic chemotherapy regimen * at least one week since prior hormonal therapy directed at malignant tumor * concurrent hormone replacement therapy allowed * recovered from prior radiotherapy * recovered from recent prior surgery * at least 3 weeks since any prior therapy directed at malignant tumor * no prior anticancer therapy that would preclude study * no concurrent amifostine or other protective agents
centrimag ventricular assist system in treating failure-to-wean from cardiopulmonary bypass

Conditions: Heart Failure

Summary: the purpose of the study is to evaluate the safety and effectiveness of the centrimag ventricular assist system to help patients who have experienced heart failure during surgery and cannot be removed from cardiac bypass.


Eligibility criteria:
inclusion criteria: * at least 18 years of age * cardiac dysfunction due to failure-to-wean from cardiopulmonary bypass * subjects who are on iabp, cpb, ecmo or cps support prior to evaluation should have the device turned off, if possible, for the purpose of measuring inclusion hemodynamics. however, these devices should not be turned off in patients who would be harmed by interruption of support. * all subjects must meet the following criteria at the time of enrollment: * hemodynamics: 1. cardiac index ≤ 2.2 l/min/m2 2. for patients being evaluated for left-sided support (lvad): pcwp ≥ 18 mmhg or padp ≥ 18 mmhg or lap ≥ 18 mmhg 3. for patients being evaluated for right or biventricular support: cvp ≥ 15 mmhg or rap ≥ 15 mmhg and rvswi ≤ 4.1 gm/m2/beat 4. enrollment without hemodynamic measurements due to frequent or unpredictable dysrhythmias, unacceptable cardiac function, or hemodynamic instability is allowed. * placement of an intra-aortic balloon pump has been attempted unless contraindicated * all possible measures have been attempted to correct low arterial ph, arterial blood gas abnormalities, electrolytes, hypovolemia, hypervolemia, inadequate cardiac rate, dysrhythmias and residual hypothermia * cardiac resuscitation using pharmacologic agents, and epicardial pacing (if appropriate and possible) has been attempted * written, signed, and dated informed consent exclusion criteria: * bun \> 100 mg/dl * creatinine \> 5 mg/dl * presence of any investigational mechanical circulatory support device * known history of liver cirrhosis or portal hypertension * pulmonary infarction * stroke, tia or history of either condition within the last six months and/or any confirmed, existing neurologic deficits * active systemic infection defined as positive blood cultures, core temperature \>100.5 degrees, white blood count \> 12,500, and treatment with antimicrobials * participation in a clinical trial with any experimental treatment within 30 days prior to screening or previous participation in the present study * other serious disease(s) limiting life expectancy

Keywords: cardiac dysfunction failure-to-wean from cpb centrimag levitronix thoratec corporation
neural correlates of cognition in parkinson's disease

Conditions: Parkinson Disease

Summary: cognitive impairment in parkinson's disease (pd) has far-reaching effects on both motor outcomes and quality of life in pd patients. furthermore, deep brain stimulation (dbs), now an evidence-based treatment for certain cases of pd, has the risk of causing deficits in multiple areas of cognition. as such, the purpose of this study is to understand the neuroanatomical and neurophysiologic basis for impaired cognition in pd. the aim is to identify neural correlates of cognition by measuring brain signal activity while pd patients are engaged in cognition on a computer.

study participants: for this study, the investigators will recruit 75 parkinson's disease (pd) patients that are undergoing deep brain stimulation (dbs) as routine standard of care. screening: for healthy control participants, investigators will approach adults, aged 18-90, for possible involvement in our study. potential participants will be asked if they have ever been diagnosed with a movement disorder, psychiatric disorder, or dementia. for pd patients undergoing evaluation for dbs, investigators will first consult with their neurologist and neurosurgeon. next, investigators will approach the participant and explain the study. pd participants: as part of the usual dbs process at university of florida (uf), pd participants will be asked to participate in this trial. there are three evaluation time points: before surgery, during surgery, and possibly after surgery. before surgery, the pd patients will complete standardized questionnaires and be trained on a computer game to assess cognition. during surgery, the participants will play the same computer game while brain signals are recorded. when the patients return to university of florida for dbs programming visits within 48 months after surgery, they will repeat the standardized questionnaires and computer game once again.

Eligibility criteria:
pd-dbs participants: * inclusion criteria: persons undergoing dbs surgery for the implantation of electrodes for the treatment of motor disorders * exclusion criteria: failure of the dbs surgical candidacy screening process non-dbs pd participants: * inclusion criteria:persons diagnosed with idiopathic parkinson's disease and have not received and are not currently scheduled for dbs. * exclusion criteria: individuals that : * that have been diagnosed with dementia or other serious brain diseases or disorders such as strokes, traumatic brain injury, or brain tumor (the exception is parkinson's disease) * who have had drug or alcohol abuse within the past 12 months * with severe sensory difficulties such as impaired vision or hearing * currently experiencing significant depression or sadness * with a history of schizophrenia or other serious mental health problems * using cognitive medications (e.g., aricept) or stimulants (e.g., adderall) * who have undergone deep brain stimulation, fetal cell implants, or other brain surgeries

Keywords: parkinsons disease cognition
evaluation of novel point of care coagulation system in pregnant women

Conditions: Hemorrhage; Coagulation Delay

Summary: in this study the investigators will evaluate a new point of care quantra hemostasis analyzer system to assess coagulation rapidly with ease.

unexpected bleeding continues to be an issue that confronts anesthesiologists. obstetric bleeding spearheads as the leading cause of maternal mortality and morbidity. one of the hurdles that clinicians confront is a lack of point of care coagulation system that can hasten the clinical management strategy in the right direction. conventional methods take considerable time to obtain results. teg and rotem are currently doing the job however these two modalities requires expertise and proficient training to perform test and interpret results. the level of expertise to run the teg and rotem poses hurdles for providing coagulation around the clock as it requires trained operators. what is currently required for efficient and effective management of obstetric hemorrhage is a point of care coagulation system in the operating room and or labor and delivery suite that is user friendly, easy and quick to perform. in this study the investigators will evaluate a new point of care quantra hemostasis analyzer system to assess coagulation rapidly with ease.

Eligibility criteria:
inclusion criteria: * pregnant woman at 37-41 weeks gestation exclusion criteria: * hypertension * preeclampsia * gestational diabetes * preexisting coagulopathy * history of deep vein thrombosis (dvt) * medications that impair coagulation * history of pulmonary embolism or thrombosis * women in active labor receiving intravenous fluids or oxytocin
fecal dna methylation test for colorectal cancer screening

Conditions: Colorectal Cancer; Colorectal Adenoma

Summary: this is an observational, prospective study using fecal dna methylation test to define the risk of suffering from advanced adenoma or colorectal cancer (crc) compared to colonoscopy and fecal immunochemical test (fit). this study recruits at least 80 participants, including 40 people of healthy controls, 20 people with adenoma, and 20 people with crc, which were confirmed by colonoscopy. all fecal specimens from participants will be examined by fit and multi-methylated target gene detection through real-time quantitative methylation-specific pcr (qmsp). the objective of this study is to evaluate the sensitivity and specificity of multi-methylated target pcr compared with the fit and confirm the examination results through colonoscopy.

the incidence rate and the mortality rate of colorectal cancer (crc) have been steadily increasing worldwide. early detection of crc can provide great opportunities to help patients, increasing their 5-year survival rate. colonoscopy has been considered as the golden standard of crc screening method, but the invasive procedures cannot be widely adapted by recipients. nowadays, the most common crc screening method is fecal immunochemical test (fit) which is a cost-effective and non-invasive approach. the sensitivity of fit for crc detection is about 80%, but only 20% for adenoma. the methylation level of candidate genes are determined by qmsp to estimate the risk of colorectal cancer. this study implements fecal dna methylation test and fecal immunochemical test simultaneously to evaluate whether the fecal dna methylation test can improve the detection rate of adenoma and crc.

Eligibility criteria:
inclusion criteria: * participants with age over 40 but under 80, who need to take colonoscopy or diagnostic confirmed colorectal cancer patient. exclusion criteria: * participants who are undergoing cancer treatments or have diagnosed with cancer, received cancer treatment in the past. * participants who have received any cancer treatments, including chemotherapy and radiotherapy before taking surgery. * participants have received any surgery for colorectal cancer in the past. * pregnant women or nursing women.

Keywords: fecal immunochemical testing methylation stool colonoscopy
small airway inflammation and dysfunction in different asthma phenotypes

Conditions: Asthma

Summary: small airway inflammation and dysfunction will be measured in 40 children and 40 adults with asthma before and after 8 weeks of treatment with inhaled budesonide. the same measurements will be conducted once in 80 age and sex matched healthy controls.


Eligibility criteria:
inclusion criteria: * symptoms of asthma and objective evidence of variable or reversible airway obstruction according to at least one of the following criteria * significant response to bronchodilator (in subjects 7 years or older: fev1 (forced expiratory volume in 1st second) or fvc (forced vital capacity) increases at least 12 % and 200 ml; in 4-6 years old subjects r5 decreases at least 40 %) * in at least 12 years old subjects significant diurnal variation (at least 20 % and 60 l/min on at least three days) or significant response to bronchodilator ( at least 15 % and 60 l/min on at least three occasions) in pef (peak expiratory flow) during a two-week monitoring * significant airway hyperreactivity (pd20 fev1 of methacholine less than 600 µg in at least 16 years old subjects, fev1 decreases at least 15 % in exercise test in 7-15 years old, or r5 increases at least 40 % during free-running test in 4-6 years old subjects) exclusion criteria: * current smoking * regular anti-inflammatory asthma medication (will be paused for at least 4 weeks before enrollment) * other chronic pulmonary disease * other diseases that in the opinion of the treating physician prevents participation
time efficiency and obturation quality of rotary versus manual in primary teeth

Conditions: Endodontic Disease

Summary: the aim of this study is to evaluate the quality of obturation and the time efficiency of rotary versus manual instrumentation in roots of deciduous molars clinically where the: * primary objective is to evaluate the time efficiency * secondary objective is to evaluate the quality of obturation clinical and radiographical follow up will be performed for 18 months to investigate the clinical and the radiographic success for the conventional and rotary groups.

the study will be conducted in two parts as follows: in-vitro part as a training part to practice, test the speed of the rotary system, followed by application clinically. obturation will be done using two different filling techniques: * incremental filling technique * disposable syringe technique. then the instrumentation time and the quality of obturation will be recorded. the study will be conducted by recruiting patients from the outpatient clinic of the pediatric dentistry and dental public health department, faculty of dentistry, ain shams university:

Eligibility criteria:
inclusion criteria: - children included in the study should conform to the following criteria: 1. patients between ages 4-7 years old with at least one mandibular vital or non-vital primary molar indicated for pulpectomy will be selected. 2. absence of periapical or interadicular radiolucencies, inflammatory root resorption, sinus tract or gingival abscess. 3. no physiological root resorption. 4. the teeth should have enough coronal structure for full coverage stainless-steel crowns. exclusion criteria: * 1. children who are extremely uncooperative and difficult to manage 2. children suffering from any physically or mentally disability that will complicate the treatment: special health care needs (shcn) 3. teeth of poor prognosis due to presence of an abscess or a sinus, mobility, advanced bone or root resorption or non-restorable teeth.

Keywords: rotatry instrumentation
measurement of left and right atria from ct scans of cardiac rhythm disorder cases

Conditions: Atrial Fibrillation

Summary: the purpose of this study is to gather information about the size and shape of patients' hearts in order to design a device.

correct device design depends on getting good information about the shape and size of the different parts of the heart. measurements from computed tomography images of hearts will be studied. by looking at measurements from a wide range of patients, an understanding of the differences in the size and shape of the heart chambers will be gained.

Eligibility criteria:
inclusion criteria: * patients deemed suitable for treatment of atrial fibrillation by catheter-based ablation who have received cardiac ct imaging as part of normal care. exclusion criteria: * patients who have not received cardiac ct imaging as part or normal care.